DoP implements PLI scheme for pharmaceuticals with a financial outlay of Rs 15,000 cr
The scheme provides a financial incentive to 55 selected applicants for manufacturing of identified products under three…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
complex generics
Credit profile of Indian pharma cos to remain healthy in FY2025 despite moderation in revenue…
Revenue growth to moderate to 8-10 per cent in FY2025, post a healthy 13-14 per cent YoY expansion in FY2024
Pharma industry headwinds in remission: ICRA
Revenues of ICRA’s sample set to grow by 7-9 per cent in FY2024; OPM to stabilise at 20.5-21.5 per cent in FY2024
Stability of input costs, specialty product launches to support performance of Indian pharma…
Revenues of ICRA’s sample set expected to grow by 6-8 per cent in FY2023 and FY2024; operating profit margins to stabilise at…
The (pharma) sector is learning to create capabilities in innovative R&D rapidly
Dr Sanjay Kumar Jain, President - India Operations, Amneal Pharmaceuticals speaks about the emerging trends in pharma R&D,…
Amneal completes acquisition of Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals is focused on the development of complex generics, innovative drug delivery platforms and novel…
Innovation – The next frontier
Alok Ghosh, Ex-President - Global Technical Operations, Lupin, underscores the importance of creating a conducive environment to…
Slayback Pharma announces investment of $50 million by The Everstone Group
The new capital will be used to expand and accelerate further Slayback’s pipeline of complex generic and specialty pharmaceutical…